Adaptive Biotechnologies ADPT 深 沪
已收盘 10-02 16:00:00 美东时间
28.35
+0.980
+3.58%
华盛通- 最 高28.41
- 今 开27.59
- 成交量 157.54万股
- 最 低 27.31
- 昨 收 27.37
- 总市值 45.25亿
- 52周最高 29.9599
- 市盈率 静 --
- 换手率 0.99%
- 52周最低 12.00
- 委 比 -89.26%
- 总股本 1.60亿
- 历史最高 71.25
- 量 比 0.55
- 振 幅 4.02%
- 历史最低 2.28
- 每 手 1
- 风险率 4.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
<p>A new consensus definition for curing multiple myeloma has been established, requiring five years of complete remission without treatment and sustained measurable residual disease (MRD) negativity. The definition includes at least four negative MRD assessments using next-generation sequencing or flow cytometry with sensitivity of 10⁻⁶, advanced imaging showing no disease, and no positive results in between. This marks a significant milestone i...
09-25 12:03
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
Adaptive Biotechnologies Highlights NCCN Guideline Updates Naming clonoSEQ For MRD Assessment In Multiple Myeloma
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (N...
09-17 20:07
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
National Comprehensive Cancer Network (NCCN) Guidelines for Multiple Myeloma have been updated to emphasize the importance of minimal residual disease (MRD) assessment, introducing a dedicated page for MRD testing principles. The guidelines recommend using next-generation sequencing (NGS) with FDA-approved assays like clonoSEQ for bone marrow-based MRD assessment, with a preferred sensitivity of 10⁻⁶. Additionally, MRD testing is now recommended ...
09-17 12:00
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of ServiceTitan Inc (NASDAQ:TTAN) fell sharply in pre-market trading after the company reported second-quarter financial results and issued third-quarter sales guidance with its midpoint below e...
09-09 20:02
财报速睇 | Adaptive Biotechnologies 2026财年Q2营收0.72亿美元，同比增长21.5%；归母净利润亏损0.40亿美元，同比亏损扩大55.3%
华盛资讯8月9日讯，Adaptive Biotechnologies公布2026财年Q2业绩，公司Q2营收0.72亿美元，同比增长21.5%，归母净利润亏损0.40亿美元，同比亏损扩大55.3%。
08-09 02:18
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
